Is Compounded Semaglutide Still Legal? What the FDA Actually Says

Semaglutide and tirzepatide get treated as one topic in most coverage of compounding legality — same shortage story, same rules, just a different molecule. They are not the same story. The FDA resolved these two shortages roughly four months apart, litigated the resulting compounding fight in two different federal dockets, and closed the enforcement-discretion window on two different dates. The rules that applied once each shortage ended are the same rules — but "the same rules, applied on a different day" is not "the same situation," and treating them as interchangeable is how a lot of secondary coverage gets the semaglutide question wrong.

Here is what FDA's own record says about semaglutide specifically, read directly off the agency's site rather than carried over from what turned out to be true for tirzepatide.

The shortage that made compounding possible

Compounding pharmacies get narrow legal room to make a copy of a patented, FDA-approved drug under sections 503A and 503B of the Food, Drug and Cosmetic Act, and a national drug shortage is the biggest of those exceptions. While a brand-name drug sits on FDA's shortage list, both 503A pharmacies (compounding for one named patient) and 503B outsourcing facilities (compounding in batches) get room to fill the gap without that counting as an illegal copy of a commercial product¹.

Semaglutide — sold under the brand names Ozempic (type 2 diabetes) and Wegovy (chronic weight management) — had been on that shortage list since 2022, the same year tirzepatide joined it, driven by the same nationwide demand spike¹. That overlap is exactly why the two compounds get lumped together. What happened next didn't run on the same clock.

FDA's semaglutide timeline, read from the agency's own updates

• •February 21, 2025 — FDA determined the semaglutide injection shortage was resolved, based on the manufacturer's confirmed ability to meet national demand — the same kind of determination FDA had already made for tirzepatide, but four and a half months later². FDA gave 503A pharmacies until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, before treating shortage-based compounding as a violation¹.
• •April 24, 2025 — a federal district court denied a preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.) — a separately docketed case from the one that resolved tirzepatide's litigation. Per FDA's own update, that ruling meant 503A enforcement discretion for semaglutide "has ended" immediately; the 503B grace window continued to run through its already-scheduled May 22, 2025 end date, unaffected by the ruling¹.

That comparison is the finding most coverage skips: it isn't that semaglutide "went through the same thing" as tirzepatide. It went through the same kind of thing, on its own schedule, litigated in its own case. Tirzepatide's compounding industry lost its enforcement-discretion window on March 5, 2025. Semaglutide's kept running for another seven weeks, into late April.

What "the shortage is over" closes off for semaglutide

A 503A pharmacy can't compound a drug that's "essentially a copy" of a commercially available product — and once FDA calls a shortage resolved, semaglutide counts as commercially available again. FDA's own guidance treats a compounded drug as "essentially a copy" when it shares the approved product's active ingredient, a similar or substitutable strength, and the same route of administration, unless a prescriber documents that a specific change is clinically necessary for that individual patient¹.

503B facilities face the separate, narrower gate every outsourcing facility runs into once a shortage clears: they can compound from a bulk drug substance only if that substance sits on FDA's "503B bulks list," or the finished drug is currently on the shortage list. As of FDA's most recent update to this page, semaglutide is on neither list — the same dead end tirzepatide hit¹. The 503B pathway is closed for both compounds identically; that part genuinely is the same situation.

FDA does leave one narrow 503A allowance standing, and it isn't drug-specific: the agency says it doesn't currently intend to act against a pharmacy that fills four or fewer prescriptions of an essentially-a-copy compounded drug in a calendar month¹. That's a patient-specific safety valve, not a basis for a telehealth subscription business selling at scale.

The detail unique to semaglutide: the B12 question

One thing FDA's guidance addresses that has no real tirzepatide equivalent: a huge share of the compounded-GLP-1 market sells semaglutide combined with vitamin B12 (cyanocobalamin) — a common upsell across the telehealth providers on this site's own board. FDA's page directly addresses whether that combination counts as "essentially a copy" of the single-ingredient branded product, and says yes, under the same conditions as a single-ingredient product: same route of administration, and the semaglutide (and B12) amounts within 10% of the approved product's strength¹. Adding a second ingredient doesn't create a loophole around the essentially-a-copy test — FDA's guidance treats the combination the same way it treats plain compounded semaglutide, once the shortage that would have excused it is over.

What remains legal in 2026

Reading FDA's own conditions rather than a summary of them, compounded semaglutide stays on solid legal footing in a few specific situations, structurally identical to tirzepatide's:

• •A prescriber documents an individualized reason a specific patient needs a dose or formulation the commercial product doesn't offer.
• •A patient has a verified allergy or intolerance to an inactive ingredient in the commercial product.
• •A pharmacy stays under the four-prescriptions-per-month threshold for what would otherwise count as "essentially a copy."

What it doesn't cover, per the agency's own stated position, is bulk 503A or 503B compounding simply because it's cheaper than Ozempic or Wegovy, marketed at telehealth-subscription scale, with no individualized medical justification tied to a named patient — the same finding our tirzepatide legal breakdown already reached for that compound, reached independently here for this one.

The enforcement wave hit semaglutide claims too — not just tirzepatide's

FDA's February 20, 2026 action against 30 telehealth companies is already covered on this site's tirzepatide article, built around the Mounjaro/Zepbound language those letters cited. Re-reading six of those same letters today specifically for semaglutide content turned up something that article's own framing undersells: every one of them cites semaglutide claims with equal weight to the tirzepatide claims, not as an afterthought.

Strut Health's letter (MARCS-CMS 721448) cites the claim "Semaglutide is the active ingredient in the brand medications" as false or misleading in the identical sentence structure as its tirzepatide citation. BluefitMD's letter (MARCS-CMS 721446) is the most explicit of the six: it quotes BluefitMD's own site copy verbatim — "Compounded Semaglutide (the same active ingredient as Ozempic® and Wegovy®)" — right alongside the equivalent Mounjaro/Zepbound line, both cited as implying FDA approval that compounded drugs don't have³. Kin Meds, Viv Health, and Ivim Health each got the same mislabeled-compounder finding — a product label naming the telehealth company itself as the compounder, which none of them are — applied to their semaglutide products as directly as their tirzepatide ones. 24HrDoc's letter names Ozempic and Wegovy by brand, the same way it names Mounjaro and Zepbound: "Same ingredients as: Ozempic and Wegovy." MEDVi's letter (MARCS-CMS 721455, dated the same day as several of the letters above) applies the identical mislabeled-compounder finding to MEDVi's own semaglutide product labels. Direct Meds' letter (MARCS-CMS #716822, September 9, 2025) is the earliest-dated letter on this list, citing the claim "Compounded semaglutide contains the same active ingredient as branded semaglutide" as implying an FDA approval compounded drugs don't have — no close-out letter had been issued as of this review.

None of that changes which providers are legitimate — a provider genuinely operating inside one of the exceptions above is on solid ground regardless of which compound triggered a warning letter elsewhere on its site. What it means is that a reader treating "the tirzepatide warning letter" as a tirzepatide-only finding is missing that the same letter, for these six companies, is just as much a semaglutide finding.

The freshest finding: a June 2026 letter this board's own review caught

Checking FDA's warning letter database for semaglutide specifically — rather than starting from the roster the tirzepatide article had already assembled — surfaced something newer: on June 8, 2026, FDA issued a warning letter to Eden Health International Inc., dba Eden (MARCS-CMS 728279), a provider reviewed on this board⁴. It's a different violation than the February wave's pattern. FDA's review of Eden's site in March 2026 found two issues: a compounded-product label identifying "Eden" as the compounder (it isn't, the same mislabeling issue the February letters cited), and a separate claim that Eden's compounded products are "sourced from FDA-licensed 503(a) outsourcing facilities" — which FDA calls false and misleading on its own terms, because compounding pharmacies and outsourcing facilities are never "FDA-approved" or "FDA-licensed" entities; no such designation exists under the FD&C Act for either one⁴. The letter names both semaglutide and tirzepatide products on Eden's site, not just one.

This is the newest FDA enforcement action against a compounded-GLP-1 telehealth provider this site has found on either compound — three and a half months after the February wave, and not part of it. It's a reminder that this is a moving target: a provider's legal standing on the day this article was checked isn't a permanent grade, and re-checking FDA's own database periodically, rather than trusting a summary written months earlier, is how a finding like this one gets caught at all.

How this differs from tirzepatide's situation, in practice

Reading the two records side by side rather than assuming they match:

• •Same shortage story, different resolution dates. Both compounds were declared shortage-resolved in the same general wave of GLP-1 supply stabilizing — tirzepatide first (October 2024, reaffirmed December 2024), semaglutide four and a half months later (February 2025).
• •Same legal fight, two different dockets. Both went through Outsourcing Facilities Association v. FDA litigation, but as two separately filed and separately decided cases — 4:24-cv-00953 for tirzepatide, 4:25-cv-00174 for semaglutide — with courts ruling seven weeks apart.
• •Same current dead end for 503B. Neither compound sits on the 503B bulks list or the shortage list today, so the batch-compounding pathway is equally closed for both.
• •Semaglutide carries one wrinkle tirzepatide's article doesn't need: the B12-combination guidance, relevant to a large share of what this board's own providers actually sell.
• •The enforcement record runs in parallel, not separately — the same companies, the same letters, cite both compounds together, and the newest action found (Eden, June 2026) targets both compounds in the same letter rather than singling one out.

Why this matters when you're comparing providers

None of this makes every compounding pharmacy selling semaglutide "illegal" — a provider genuinely operating inside one of the exceptions above is on solid ground, the same as any tirzepatide provider in the same position. What it means is that "compounded" and "cheap" stopped being evidence of a clever workaround once the shortage that justified scale compounding closed, on this compound just as much as tirzepatide's — and a provider whose intake never asks why a compounded dose is medically necessary for you isn't obviously operating inside the exception FDA left open.

The sharpest case is HydraMed, which FDA cited in June 2026 for putting its own name on compounded vials it did not compound and calling its compounder an "FDA-approved pharmacy" — and whose entire site now returns an error on every page. That's a pharmacy-sourcing and price-transparency question as much as a legal one, which is exactly why our semaglutide provider comparison reads pharmacy disclosures directly off each provider's own site instead of assuming "compounded" means the same thing everywhere.

Once a prescriber has actually given you a dose in milligrams, our reconstitution calculator hub converts that into the syringe volume and units it corresponds to — arithmetic on the number your prescriber gave you, not a suggestion of what that number should be.

The table below is the whole reviewed roster, one row each, alphabetical. It is deliberately dull to read top to bottom — the point is that you can find a company you are about to buy from and see, in one line, what its own pages actually say versus what its headline price implies. Same exception, same enforcement record, a full roster to read the same way rather than take at face value.